RCReid C. Chamberlain

Reid C. Chamberlain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Reid C. Chamberlain has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transcatheter Thrombus Removal With the Penumbra Indigo Lightning System in Children With Congenital Heart Disease

    by Annirudh N. Balachandran, Kevin D. Hill, Reid C. Chamberlain, Gregory A. Fleming

    Thromboembolic complications in children with congenital heart disease (CHD) carry significant morbidity and mortality, particularly in patients with single ventricle physiology. Current management strategies, including systemic anticoagulation, thrombolytics, and surgical thrombectomy, each carry substantial risks in this population. Transcatheter aspiration thrombectomy represents an emerging alternative. We retrospectively reviewed all pediatric patients with CHD at our institution who underwent transcatheter aspiration thrombectomy using the Penumbra Indigo Lightning System between January 2024 and February 2025. Patient demographics, cardiac diagnosis, thrombus location, procedural details, and clinical outcomes were recorded. Five patients (age 5 months to 9 years; weight 6.3–25.9 kg) with diverse CHD diagnoses underwent six thrombectomy procedures. Thrombus locations included the Fontan circuit, inferior vena cava, pulmonary arteries, and internal jugular veins. Technical success with angiographic restoration of antegrade flow and no residual gradient across the segment of interest, was achieved in all cases (100%). Blood loss ranged from 6 to 23 mL/kg; all patients required packed red blood cell transfusion. No significant intraprocedural hemodynamic instability occurred. Three patients were discharged home with confirmed vessel patency on follow‐up imaging (echocardiography and/or vascular ultrasound at 4–6 months post intervention). Two patients, both on extracorporeal membrane oxygenation (ECMO) support prior to the procedure, subsequently died from causes unrelated to the thrombectomy intervention. In this limited case series, the Penumbra Indigo Lightning System demonstrated feasibility for transcatheter thrombus removal in pediatric patients across a spectrum of CHD. Given the limited number of available catheter systems in this population, this approach may be considered as a first‐line or adjunct therapy in select patients when conventional medical management is insufficient or contraindicated. Further prospective studies are needed to define optimal patient selection, procedural techniques, and post‐procedural management.

  • Open Access

    Prescription Patterns of Cardiovascular Medications in the Adolescent and Adult Population With Fontan Circulation—A Report From the Multicenter Single Ventricle Outcomes Network

    by Andrew M. Freddo, Humera Ahmed, Jonathan B. Edelson, Sara Partington, Emily Ruckdeschel, Allison L. Tsao, Juan M. Ortega‐Legaspi, Yuli Y. Kim, Adeola O. Awujoola, Deepti P. Bhat, et al.

    Background: There are limited data on prescription patterns in adolescents and adults with Fontan circulation. Methods: We conducted a retrospective analysis of patients 13 years of age and older enrolled between 2022 and 2024 in the Fontan Outcomes Network (now SV‐ONE [Single Ventricle Outcomes Network]) who had undergone Fontan operation without subsequent Fontan takedown or heart transplantation. Demographics, clinical variables, and medications prescribed were assessed. Logistic regression was used to identify factors associated with prescribed cardiac medications. Results: There were 639 patients (age range 13–67 years, 55.6% male, 81.1% White race, 46.8% dominant left ventricle) enrolled at 16 centers. The most frequently prescribed medication classes were antiplatelets (75.6%) and renin‐angiotensin system inhibitors (55.9%). Direct oral anticoagulant prescription (15.0%) exceeded that of warfarin (11.6%). SGLT2 (sodium glucose cotransporter 2) inhibitors were prescribed to 6.3% of patients, and angiotensin receptor/neprilysin inhibitors were prescribed to 2.2%. Moderate or severely decreased systolic ventricular function was most strongly associated with prescription of digoxin (odds ratio [OR], 4.2 [95% CI, 2.1–8.3]). Protein losing enteropathy was most strongly associated with prescription of diuretics (OR, 22.9 [95% CI, 8.1–64.9]), mineralocorticoid receptor agonists (OR, 5.3 [95% CI, 2.4–11.8]), and pulmonary vasodilators (OR, 5.2 [95% CI, 2.5–10.8]). Conclusions: In a multicenter cohort of adolescents and adults with Fontan circulation, medications indicated for biventricular heart failure with reduced ejection fraction are often used despite an absence of supportive evidence in this distinct circulation. Future prospective analysis may provide further insight into shifting prescribing patterns and response to therapy.

  • Review of Management of the Borderline Left Ventricle: A Focus on Current Transcatheter and Hybrid Approaches

    by Bassel Mohammad Nijres, Reid C. Chamberlain, Rachel A. Taylor, Rupesh Natarajan, Cauyna Moreira, Thomas K. Jones

    A borderline small left ventricle (LV), in which the LV is underdeveloped but not diminutive, represents an ongoing area of research and a challenge in clinical management. In this paper, the authors aimed to review the definition of borderline LV and recruitment strategies with a focus on hybrid, and wholly transcatheter approaches, to achieve the goal of two ventricle circulation. Hampered by a lack of consensus definition; historically, patients with borderline LV were managed with single-ventricle palliation. However, due to the suboptimal long-term outcomes with single-ventricle palliation, many programs have adopted strategies to promote LV growth with the goal of achieving two-ventricle circulation with different outcomes. Initially dominated by surgical staging, there is growing evidence to support the use of hybrid or entirely transcatheter techniques to achieve first stage palliation in patients with borderline LV. Regardless of technique used (surgical and/or transcatheter), recruiting the LV into a successful biventricular circulation typically requires multiple interventions aimed at improving blood flow through the left heart structures and increasing LV volume loading in an effort to promote LV remodeling. Scoring systems can be helpful tools in determining the candidacy for LV recruitment strategy; however, the optimal scoring system has yet to be established.

  • Open Access

    Trends in Radiation Exposure With the Refinement of Radiation Exposure Categories in Congenital Cardiac Catheterization: Insights From the CRISP Registry

    by Gurumurthy Hiremath, Juan Carlos Samayoa, Alexander Javois, Osamah Aldoss, Ryan Leahy, Reid Chamberlain, Elena Amin, Marko Vezmar, Makram Ebeid, Shyam Sathanandam, et al.


  • Urine biomarkers, acute kidney injury, and fluid overload in neonatal cardiac surgery

    by Rebecca D. Sullenger, Alison G. Kilborn, Reid C. Chamberlain, Kevin D. Hill, Rasheed A. Gbadegesin, Christoph P. Hornik, Elizabeth J. Thompson

    Background: Cardiac surgery-associated acute kidney injury (CS-AKI) and fluid overload (FO) are common among neonates who undergo cardiopulmonary bypass, and increase mortality risk. Current diagnostic criteria may delay diagnosis. Thus, there is a need to identify urine biomarkers that permit earlier and more accurate diagnosis.Methods: This single-centre ancillary prospective cohort study describes age- and disease-specific ranges of 14 urine biomarkers at perioperative time points and explores associations with CS-AKI and FO. Neonates (≤28 days) undergoing cardiac surgery were included. Preterm neonates or those who had pre-operative acute kidney injury were excluded. Urine biomarkers were measured pre-operatively, at 0 to < 8 hours after surgery, and at 8 to 24 hours after surgery. Exploratory outcomes included CS-AKI, defined by the modified Kidney Disease Improving Global Outcomes criteria, and>10% FO, both measured at 48 hours after surgery.Results: Overall, α-glutathione S-transferase, β-2 microglobulin, albumin, cystatin C, neutrophil gelatinase-associated lipocalin, osteopontin, uromodulin, clusterin, and vascular endothelial growth factor concentrations peaked in the early post-operative period; over the sampling period, kidney injury molecule-1 increased and trefoil factor-3 decreased. In the early post-operative period, β-2 microglobulin and α-glutathione S-transferase were higher in neonates who developed CS-AKI; and clusterin, cystatin C, neutrophil gelatinase-associated lipocalin, osteopontin, and α-glutathione S-transferase were higher in neonates who developed FO.Conclusion: In a small, single-centre cohort, age- and disease-specific urine biomarker concentrations are described. These data identify typical trends and will inform future studies.


  • Additive value of invasive haemodynamic assessment for predicting post-operative outcomes after Fontan

    by Kathleen P. Wood, Kristin E. Bonello, Sarah T. Plummer, Reid C. Chamberlain, Greg A. Fleming, Michael G.W. Camitta, Kevin D. Hill

    Routine pre-Fontan cardiac catheterization remains standard practice at most centres. However, with advances in non-invasive risk assessment, an invasive haemodynamic assessment may not be necessary for all patients.Using retrospective data from patients undergoing Fontan palliation at our institution, we developed a multivariable model to predict the likelihood of a composite adverse post-operative outcome including prolonged length of stay ≥ 30 days, hospital readmission within 6 months, and death and/or transplant within 6 months. Our baseline model included non-invasive risk factors obtained from clinical history and echocardiogram. We then incrementally incorporated invasive haemodynamic data to determine if these variables improved risk prediction.Our baseline model correctly predicted favourable versus adverse post-Fontan outcomes in 118/174 (68%) patients. Covariates associated with adverse outcomes included the presence of a systemic right ventricle (adjusted adds ratio [aOR] 2.9; 95% CI 1.4, 5.8; p = 0.004), earlier surgical era (aOR 3.1 for era 1 vs 2; 95% CI 1.5, 6.5; p = 0.002), and performance of concomitant surgical procedures at the time of Fontan surgery (aOR 2.5; 95% CI 1.1, 5.0; p = 0.026). Incremental addition of invasively acquired haemodynamic data did not improve model performance or percentage of outcomes predicted.Invasively acquired haemodynamic data does not add substantially to non-invasive risk stratification in the majority of patients. Pre-Fontan catheterization may still be beneficial for angiographic evaluation of anatomy, for therapeutic intervention, and in select patients with equivocal risk stratification.

  • Hybrid approach to pulmonary vein stenting after Fontan palliation

    by Daniel R. Critchfield, Reid C. Chamberlain, Joseph W. Turek, Gregory A. Fleming

    Pulmonary vein stenosis is poorly tolerated in patients who have undergone Fontan palliation and typically requires surgical or transcatheter intervention. Percutaneous transcatheter approaches to intervention can be technically difficult due to challenging anatomy. A hybrid per‐atrial transcatheter approach for stenting pulmonary veins provides a direct approach to the pulmonary veins and has the potential to improve safety and efficacy of this complex intervention. We describe our experience with hybrid per‐atrial pulmonary vein stenting in three patients with pulmonary vein stenosis following Fontan palliation.


  • Update on Transcatheter Device Closure of Congenital Septal Defects

    by Kathleen P. Wood, Gregory A. Fleming, Reid C. Chamberlain

    Purpose of Review The goal of this paper is to review currently available devices for closure of atrial septal defects (ASDs) and ventricular septal defects (VSDs). Recent Findings Favorable results from the ASSURED trial resulted in FDA approval for the most recently developed device for transcatheter ASD closure in the United States. Further studies are required to assist in the development or approval of safe devices for transcatheter perimembranous VSD closure in pediatric patients. Summary Device closure is the less invasive and preferred management option for many ASDs, with multiple studies demonstrating lower complication rates, shorter hospital stays, and lower mortality than surgical repair. Complex ASDs that make device closure more difficult include large defects, rim deficiencies, fenestrated defects, multiple defects, and the presence of pulmonary arterial hypertension. Device closure has also become an accepted alternative to surgery for some types of ventricular septal defects VSDs, though challenges and limitations remain. Future innovations including novel devices and techniques are needed to further expand on the types of defects that can be safely closed via transcatheter approach.


  • Whole-Chest Three-Dimensional Modeling Aids Hybrid Pulmonary Valve Replacement Following Double Switch Operation

    by Philip Carmon, Gregory A Fleming, Piers C A Barker, Gregory M Sturgeon, Joseph W Turek, Reid C Chamberlain

    The double switch operation for congenitally corrected transposition of the great arteries (CC-TGA) has been associated with high rates of reintervention, including the need for pulmonary valve replacement. Hybrid interventional approaches can avoid bypass when complex anatomy complicates traditional catheter-based approaches. We present a case of successful transcatheter pulmonary valve replacement via hybrid per-ventricular approach with pre-procedural planning aided by 3D segmentation of skeletal and cardiac anatomy in a patient with surgically corrected CC-GTA.

  • Characterization of hemodynamics in anomalous aortic origin of coronary arteries using patient-specific modeling

    by Simbarashe G. Chidyagwai, Madhurima Vardhan, Michael Kaplan, Reid Chamberlain, Piers Barker, Amanda Randles